How do you decide if a fractional Chief Revenue Officer is right for a Series A company when preparing for fundraise in six months?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Anchor: Series A Fundraise Prep

This is not a seed-stage company where revenue is optional for investors, nor a Series B where predictable growth and unit economics are table stakes. At Series A with a six-month fundraise window, the company typically has $1M–$3M ARR, a handful of referenceable customers, and a product that works but a sales motion that is inconsistent. The fundraise timeline means every revenue decision from here on is judged by a venture capital (VC) partner who will scrutinize pipeline hygiene, sales cycle length, and whether the company can double ARR in the next 12 months without founder burnout. The fractional CRO must simultaneously fix the sales engine and produce investor-ready metrics, which is a dual mandate that a full-time VP of Sales often cannot handle because they focus on closing, not narrative building.

Buying Dynamics

The buying committee at Series A companies preparing for fundraise is not the typical customer buying committee – it is the VC partner, the lead investor, and the board observer. The fractional CRO must sell to these three people, not to prospects. The VC partner evaluates whether the company has a defined ICP (ideal customer profile) with clear demographic and firmographic criteria, a repeatable sales process with documented stages and exit criteria, and a revenue leader who can articulate why the company will hit $5M ARR in 12 months. The lead investor looks for pipeline coverage (ratio of weighted pipeline to quarterly target, which must be at least 3x) and whether the sales team can forecast within 15% accuracy. The board observer wants to see that the founder is not the top closer – if the founder still owns 80% of revenue relationships, the company is not investable.

Typical deal size and shape for Series A B2B SaaS companies is $20K–$50K annual contract value (ACV) for mid-market, with sales cycles of 60–90 days. If the company is selling enterprise deals above $100K ACV, the cycle extends to 120–180 days, which is too long for a six-month fundraise timeline because investors want to see closed-won deals within the next two quarters. The fractional CRO must force a pivot to smaller, faster deals if the ACV is above $50K, because the fundraise clock does not wait for enterprise procurement.

Budget approval at Series A is still founder-controlled, but the fractional CRO must shift budget decisions from the founder to a defined sales compensation plan with quotas, accelerators, and clawbacks. Investors will ask: "Who approves the discount on a $30K deal?" If the answer is the founder, the company has no scalable sales model. The fractional CRO must implement a deal desk process where discounts above 15% require a second approval from the CRO, not the CEO.

Where deals stall at Series A is almost always in the evaluation stage because the sales team lacks case studies, ROI calculators, or competitive battle cards. The fractional CRO must commission three detailed customer success stories with specific metrics (e.g., "Customer X reduced time-to-value by 40%") within 60 days, because investors will ask for reference calls and the sales team needs proof points to unstick deals. Deals also stall on pricing because the founder has been negotiating every deal individually, creating a patchwork of discounts that destroys gross margin – the fractional CRO must standardize pricing to a single rate card with volume tiers.

Sales-Cycle Implications

The motion this situation forces is a compressed, investor-facing sales cycle where the fractional CRO must produce a 6-month revenue forecast that aligns with the fundraise narrative. This means the CRO cannot use a traditional "land and expand" motion because that takes 12–18 months to show results. Instead, they must focus on "land and reference" – closing deals that will become reference accounts for the fundraise, even if the ACV is lower than target. The motion is also forced to be outbound-heavy because inbound leads at Series A are typically low volume (50–100 per month) and cannot fill the pipeline needed for a 3x coverage ratio. The fractional CRO must build a sequence of 500 targeted prospects per month using LinkedIn Sales Navigator and a simple email cadence, because the company cannot afford a full SDR team yet.

Ramp and forecast behavior is the single biggest risk for a fractional CRO in this situation. A new hire, even fractional, needs 30 days to understand the product, the customer base, and the existing pipeline. They cannot produce a reliable forecast until day 45. The fundraise timeline means the CRO must produce a credible 12-month forecast by month three, which is unrealistic for a full-time VP of Sales who is still learning the business. The fractional CRO must use a "weighted pipeline by stage" model with explicit probabilities (e.g., demo: 10%, proposal: 30%, negotiation: 60%) and update it weekly. The forecast behavior must be conservative – if the CRO says the company will close $500K in Q3, the founder should budget for $350K. Investors will punish over-promising more than under-promising.

Pipeline shape at Series A is typically a flat line – there are a few big deals in late stage and nothing in early stage. The fractional CRO must reshape the pipeline into a pyramid: 50% of pipeline in early stage (discovery or demo), 30% in mid stage (proposal or evaluation), and 20% in late stage (negotiation or closed-won). This requires the CRO to personally source 20–30 new opportunities per month through their network and cold outreach, because the founder cannot do this while also preparing for fundraise. The pipeline must also be diversified across at least three buyer personas (e.g., head of sales, head of marketing, head of operations) to show investors that the product has multi-departmental appeal.

Where the leaks are is almost always in the handoff from marketing to sales and from sales to implementation. The fractional CRO must audit the current handoff process: how many marketing-qualified leads (MQLs) convert to sales-accepted leads (SALs)? If it is below 20%, the CRO must implement a lead scoring system using firmographic data (company size, industry, title) and behavioral data (website visits, demo requests). The other leak is in the implementation phase – if customers sign but do not go live within 30 days, churn risk increases and investors will question customer success. The fractional CRO must enforce a 30-day onboarding SLA with a dedicated customer success manager (even if it is the CRO themselves) for every new deal.

What a Fractional / Interim / Full-Time Revenue Leader Looks Like Here

The first 90 days for a fractional CRO at a Series A company preparing for fundraise is not about closing deals – it is about building the revenue story for investors. Day 1–30: audit the existing pipeline, customer base, and sales process. Identify the top 10 deals that can close within 60 days and personally manage them. Day 31–60: build a 12-month revenue model with three scenarios (base, stretch, and downside) and present it to the board. Day 61–90: implement a sales playbook with defined stages, exit criteria, and a pricing standard. The fractional CRO must also produce a "revenue readiness" document for the fundraise: a one-pager that shows ARR growth rate, net revenue retention (NRR), customer acquisition cost (CAC) payback period, and pipeline coverage. This document is the single most important output because the VC partner will use it to decide whether to invest.

Operating cadence is weekly, not daily. The fractional CRO should not be in the office every day because that signals the company is paying for a full-time presence when they only need strategic direction. The cadence: Monday 30-minute pipeline review with the founder and any sales hires, Wednesday 45-minute forecast review, Friday 15-minute email update on wins and losses. The fractional CRO must also attend the board meeting each month to present revenue progress and answer investor questions. The cadence must be documented in a shared CRM (HubSpot or Salesforce) so the founder can see every deal stage change without needing to ask. The CRO should not be involved in individual rep coaching unless there are only one or two reps – at Series A, the founder is still the best coach.

What they own vs advise is the critical distinction. The fractional CRO owns the revenue forecast, the sales process, the pricing and packaging, and the fundraise narrative. They advise on hiring (when to hire the first full-time VP of Sales), on marketing spend (whether to invest in paid ads or content), and on customer success (whether to hire a CS manager or use the CRO). The founder still owns the product roadmap, the customer relationships for top 5 accounts, and the investor relationships. The fractional CRO should not own the CRM administration or the lead generation – those should be handled by a part-time SDR or an agency. If the fractional CRO starts doing data entry, they are not adding strategic value.

Signals to convert to full-time or not are clear in a Series A fundraise context. Convert to full-time if: (a) the company raises the round and now has capital to hire a permanent revenue leader, (b) the fractional CRO has built a repeatable sales process that a full-time VP can execute, and (c) the company has grown ARR by 50%+ during the fractional engagement. Do not convert if: (a) the fundraise fails and the company needs to conserve cash, (b) the fractional CRO has not been able to increase pipeline coverage above 2x, or (c) the founder still closes 60%+ of deals themselves. The conversion decision should be made by month five of the engagement, because the fractional CRO needs to either transition to full-time or hand off to a permanent hire before the fundraise closes. If the company converts, the fractional CRO should stay for at least six months post-fundraise to ensure the sales engine is stable.

FAQ

A question? How do I know if my Series A company has enough revenue to justify a fractional CRO instead of a full-time VP of Sales?

If your ARR is below $1.5M, a full-time VP of Sales is too expensive (total cost $250K–$350K) and will create pressure to hire a full team before you have the revenue to support it. A fractional CRO at $10K–$15K per month for 20 hours per week is affordable and gives you strategic guidance without the overhead. The signal to hire a fractional CRO is when the founder is spending more than 40% of their time on sales but still missing quarterly targets. If the founder is closing 80% of deals, the company is not ready for a full-time VP – they need a fractional leader to systematize the founder's process first.

A question? What happens if the fractional CRO's forecast is wrong during the fundraise due diligence?

Investors will ask for a 12-month forecast and then track actuals monthly. If the fractional CRO misses by more than 20% in the first two months, the fundraise is at risk because investors will question the company's ability to execute. To mitigate this, the fractional CRO should provide a "confidence range" for each quarter (e.g., Q3: $400K–$500K) and explain the assumptions behind the range. If the forecast is wrong, the CRO must immediately produce a revised forecast with a clear root cause analysis – was it pipeline volume, deal velocity, or pricing? The founder should also have a backup plan: a bridge round from existing investors if the Series A is delayed by 3–6 months.

A question? Should the fractional CRO be involved in the fundraise meetings with VCs?

Yes, but only in the revenue-specific sessions. The fractional CRO should attend the second or third partner meeting where the VC asks detailed questions about sales process, pipeline, and forecast. The founder should lead the fundraise narrative, but the fractional CRO should be able to answer: "How do you forecast?" "What is your win rate by stage?" "Why is your sales cycle 60 days and not 90?" The fractional CRO should also prepare a 10-slide revenue appendix for the data room that includes cohort analysis, logo churn, and sales rep productivity. If the fractional CRO cannot articulate these metrics, the VC will assume the company has no revenue discipline.

A question? How do I transition from a fractional CRO to a full-time CRO after the fundraise, and what should the compensation look like?

The transition should happen within 30 days of the fundraise closing. The fractional CRO becomes a full-time employee with a base salary of $180K–$220K (commensurate with Series A stage) and a variable component tied to ARR growth (20%–30% of base). The fractional CRO should also receive options (0.5%–1.5% of the company, vesting over 4 years with a 1-year cliff) because they have already proven they can execute. The transition requires a clear handoff of responsibilities: the fractional CRO now owns the full sales team (not just strategy), so they must hire 2–3 account executives and a sales operations analyst within the first 90 days post-fundraise. If the fractional CRO is not willing to go full-time, the company should hire a full-time VP of Sales and keep the fractional CRO on a 3-month advisory retainer to ensure continuity.

Sources